|
Canada-0-PATIO Azienda Directories
|
Azienda News:
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- FDA Approves Alectinib for ALK-Positive Lung Cancer
Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
- FDA approves alectinib as adjuvant treatment for ALK-positive . . .
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
- Disease characteristics and treatment outcomes in patients . . .
This exploratory analysis investigated whether the disease-free survival (DFS) benefit seen with adjuvant alectinib versus chemotherapy in patients with resected, ALK -positive non-small cell lung cancer (NSCLC) from the phase III ALINA study (NCT03456076) was maintained across surgical characteristic subgroups and when re-classifying patients according to the 8th edition of the Cancer Staging
- ALK and Lung Cancer - American Lung Association
ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
- Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . .
INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [1,2] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
- ALK-positive lung cancer: what it means and targeted . . .
What does ALK-positive in non-small cell lung cancer mean what are some treatment options? Georgetown University's Dr Stephen Liu shares insights
- Novel Small Molecule Earns FDA Fast Track Designation in ALK+ . . .
Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1 2 trial Investigators are currently evaluating the safety, pharmacokinetics, and preliminary activity of TRI-611 among patients with ALK-positive NSCLC as part of a phase 1 2 study (NCT07491497)
- Alectinib in combination with bevacizumab as first-line . . .
Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy This work reports a phase 2 trial
- Update 2025: Management of Non‑Small-Cell Lung Cancer - PMC
Introduction Lung cancer has remained the leading cause of cancer-related mortality worldwide since the 1950s, posing a significant global health challenge [1] NSCLC, which constitutes the majority of lung cancer cases, has historically been associated with poor outcomes due to its often late diagnosis and limited treatment options [2]
|
|